Are you in %country%? Do you want to visit our website in another language?

Circle of Excellence:
Federal President’s
Award 2022

Explore the nominated technology


Circle of Excellence: Federal President’s Award
for Innovation and Technology

Explore the nominated technology

Stefan Vilsmeier, Claus Promberger and Professor Cordula Petersen, MD were one of the three teams nominated for the Federal President’s Award for Innovation and Technology 2022 for their work on ExacTrac Dynamic® technology.



Stefan Vilsmeier, Claus Promberger and Professor Cordula Petersen, MD
were one of the three teams nominated for the Federal President’s Award for Innovation and Technology 2022 for their work on ExacTrac Dynamic® technology.

About the Award

The Federal President’s Award for Innovation and Technology has been awarded annually by the German Federal President for over 25 years and honors outstanding technical, engineering, scientific as well as software and algorithm-based achievements within Germany. The jury for the award consists of ten independent industry experts from the fields of science and medicine.

The Federal President’s Award for Innovation and Technology 2022 was given to Carl Zeiss Microscopy GmbH on October 26th, 2022.

Watch the award ceremony here:



About the Award

The Federal President’s Award for Innovation and Technology has been awarded annually by the German Federal President for over 25 years and honors outstanding technical, engineering, scientific as well as software and algorithm-based achievements within Germany. The jury for the award consists of ten independent industry experts from the fields of science and medicine.

The Federal President’s Award for Innovation and Technology 2022 was given to Carl Zeiss Microscopy GmbH on October 26th, 2022.

Watch the award ceremony here:



The Team

The Team

Our Technology

ExacTrac Dynamic

From diagnosis to treatment – learn more about patient positioning with state-of-the-art imaging technology in this video

Lung cancer is the leading cause of cancer death worldwide,
claiming around 45,000 lives per year in Germany alone.

Oftentimes, lung cancer is not diagnosed until the disease has reached a more advanced stage because lung cancer symptoms can take longer to manifest and detect. Patients move during irradiation and, due to respiration, the tumor can also move irregularly. Until now, a safety area around the tumor — referred to as the motion envelope — has been irradiated along with the tumor. The motion envelope encompasses the entire space in which the tumor moves during respiration. However, this approach can result in the destruction of healthy lung tissue, which ultimately can impair function and quality of life.

In addition, 2D X-Rays may not always be able to detect small and often treatable tumors. If these small lung tumors could be detected and treated in an early stage of disease progression, the patient’s chances of survival may increase.

Present and future of radiotherapy treatment

ExacTrac Dynamic was developed to address these challenges and limitations. With this technology, patients with different tumor types can be positioned with submillimetric precision during irradiation.

As a result, it is now possible to effectively destroy tumor tissue while sparing healthy tissue.

The potential of the technology is enormous—currently, ExacTrac Dynamic enables medical professionals to achieve high precision, submillimetric radiotherapy positioning for breast, brain, spine and prostate cancer patients. This supports the significantly more precise delivery of radiation therapy in fewer sessions than conventional radiation treatment and contributes to better quality of life for patients.

ExacTrac Dynamic is in the process of being modified so that in the future, it will be able to precisely target other types of solid tumors, including small, moving lung tumors.

For the development of this groundbreaking approach in lung cancer, Stefan Vilsmeier and Claus Promberger are in close collaboration with Prof. Cordula Petersen, whose clinical insights were incorporated into the project.

Our Technology

ExacTrac Dynamic



From diagnosis to treatment – learn more about patient positioning with state-of-the-art imaging technology in this video

Lung cancer is the leading cause of cancer death worldwide,
claiming around 45,000 lives per year in Germany alone.

Oftentimes, lung cancer is not diagnosed until the disease has reached a more advanced stage because lung cancer symptoms can take longer to manifest and detect. Patients move during irradiation and, due to respiration, the tumor can also move irregularly. Until now, a safety area around the tumor — referred to as the motion envelope — has been irradiated along with the tumor. The motion envelope encompasses the entire space in which the tumor moves during respiration. However, this approach can result in the destruction of healthy lung tissue, which ultimately can impair function and quality of life.

In addition, 2D X-Rays may not always be able to detect small and often treatable tumors. If these small lung tumors could be detected and treated in an early stage of disease progression, the patient’s chances of survival may increase.

Present and future of radiotherapy treatment

ExacTrac Dynamic was developed to address these challenges and limitations. With this technology, patients with different tumor types can be positioned with submillimetric precision during irradiation.

As a result, it is now possible to effectively destroy tumor tissue while sparing healthy tissue.

The potential of the technology is enormous—currently, ExacTrac Dynamic enables medical professionals to achieve high precision, submillimetric radiotherapy positioning for breast, brain, spine and prostate cancer patients. This supports the significantly more precise delivery of radiation therapy in fewer sessions than conventional radiation treatment and contributes to better quality of life for patients.

ExacTrac Dynamic is in the process of being modified so that in the future, it will be able to precisely target other types of solid tumors, including small, moving lung tumors.

For the development of this groundbreaking approach in lung cancer, Stefan Vilsmeier and Claus Promberger are in close collaboration with Prof. Cordula Petersen, whose clinical insights were incorporated into the project.

Learn more about our technology

ExacTrac Dynamic
Precision Patient Monitoring for Radiotherapy
Learn more
Lung Motion Management
Precise Treatment of Tumors in Motion
Learn more

Get in contact with us